We are live on
!
Find out more
RA
Rosalind Advisors Portfolio holdings
AUM
$269M
Turnover
42.22%
1-Year Est. Return
103.38%
This Fund
S&P 500
This Quarter
Est. Return
+8.81%
1 Year Est. Return
+103.38%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$211M
AUM Growth
+$5.25M
(+2.6%)
Cap. Flow
+$4.92K
Cap. Flow
% of AUM
0%
Top 10 Holdings %
Top 10 Hldgs %
62.31%
Holding
46
New
12
Increased
7
Reduced
9
Closed
9
Avg Time Held Equity + Options
0.7
years
Top 10 Avg Time Held Equity + Options
0.5
years
Top 20 Avg Time Held Equity + Options
0.8
years
Avg Time Held Equity only
0.9
years
Top 10 Avg Time Held Equity only
0.5
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cytokinetics
CYTK
|
+$13.9M |
| 2 |
Rezolute
RZLT
|
+$6.47M |
| 3 |
Delcath Systems
DCTH
|
+$5.58M |
| 4 |
CG Oncology
CGON
|
+$4.65M |
| 5 |
Myomo
MYO
|
+$3.23M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abeona Therapeutics
ABEO
|
+$8.6M |
| 2 |
Nuvation Bio
NUVB
|
+$4.31M |
| 3 |
UroGen Pharma
URGN
|
+$3.91M |
| 4 |
Verastem
VSTM
|
+$3.76M |
| 5 |
IDEAYA Biosciences
IDYA
|
+$3.62M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.99% |
| 2 | Miscellaneous | 2.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Compass Pathways
CMPS
$1.51B
| $1.35M | 0.64% |
482,651
-340,635
| -41% | -$1.28M |
2023 Q4
6 quarters
|
|
27
Talphera
TLPH
$56.1M
| $922K | 0.44% |
2,003,939
| – | – |
2023 Q4
6 quarters
|
|
28
Biofrontera
BFRI
$12.3M
| $695K | 0.33% |
976,448
+332,055
| +52% | +$232K |
2024 Q1
5 quarters
|
|
|
29
CALL
UroGen Pharma
URGN
$1.69B
| $600K | 0.28% |
+100,000
| New | +$960K |
2025 Q2
0 quarters
|
|
30
Kura Oncology
KURA
$825M
| $577K | 0.27% |
100,000
| – | – |
2025 Q1
1 quarter
|
|
31
PUT
State Street SPDR NYSE Technology ETF
XNTK
$1.92B
| $534K | 0.25% |
+550,000
| New | +$114M |
2025 Q2
0 quarters
|
|
32
CALL
Replimune Group
REPL
$1.03B
| $516K | 0.24% |
+231,800
| New | +$2.02M |
2025 Q2
0 quarters
|
|
33
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$806B
| $433K | 0.21% |
+250,000
| New | +$143M |
2025 Q2
0 quarters
|
|
34
PUT
aTyr Pharma
ATYR
$18.1M
| $271K | 0.13% |
+223,000
| New | +$877K |
2025 Q2
0 quarters
|
|
35
Ovid Therapeutics
OVID
$416M
| $165K | 0.08% |
+500,000
| New | +$151K |
2025 Q2
0 quarters
|
|
|
36
CALL
IDEAYA Biosciences
IDYA
$3.2B
| $68K | 0.03% |
+20,000
| New | +$384K |
2025 Q2
0 quarters
|
|
37
CALL
DELISTED
Crinetics Pharmaceuticals
CRNX
| $58K | 0.03% |
+52,700
| New | +$1.63M |
2025 Q2
0 quarters
|
|
|
38
Abeona Therapeutics
ABEO
$252M
| – | – |
-1,805,817
| Closed | -$8.6M | – |
|
39
PUT
Candel Therapeutics
CADL
$636M
| – | – |
-15,800
| Closed | -$3.57K | – |
|
40
Cogent Biosciences
COGT
$5.09B
| – | – |
-248,285
| Closed | -$1.49M | – |
|
41
Kiora Pharmaceuticals
KPRX
$10.4M
| – | – |
-250,059
| Closed | -$753K | – |
|
42
CALL
Lexicon Pharmaceuticals
LXRX
$690M
| – | – |
-1,278,900
| Closed | -$30K | – |
|
|
43
Nuvation Bio
NUVB
$1.58B
| – | – |
-2,451,500
| Closed | -$4.31M | – |
|
44
DELISTED
OptiNose
OPTN
| – | – |
-256,190
| Closed | -$2.35M | – |
|
45
PUT
Invesco QQQ Trust
QQQ
$476B
| – | – |
-50,000
| Closed | -$374K | – |
|
46
Alpha Cognition
ACOG
$181M
| – | – |
-104,836
| Closed | -$530K | – |
|
Similar funds
GPFA
TW
PM
ZEP
LBW
VP
5W
NF
Rosalind Advisors's Q2 2025 Portfolio in Review
As of Q2 2025, Rosalind Advisors held 46 positions worth $211M, up 2.6% from $206M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Rosalind Advisors's Q2 2025 filing shows 12 new, 7 increased, 9 reduced and 9 closed positions. Its largest new stake was Cytokinetics: 400,000 shares worth $13.2M. The largest sale was Abeona Therapeutics, an estimated $8.6M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
- Rosalind Advisors's largest Q2 2025 buy was Cytokinetics: 400,000 shares worth $13.2M.
- Rosalind Advisors added most to Delcath Systems in Q2 2025, an estimated $5.58M increase.
- Rosalind Advisors's biggest Q2 2025 reduction was UroGen Pharma, cutting an estimated $3.91M.
- Rosalind Advisors fully exited Abeona Therapeutics in Q2 2025, selling an estimated $8.6M.
- Rosalind Advisors's ten largest holdings make up 62% of its $211M portfolio in Q2 2025.
- Rosalind Advisors opened 12 new positions and closed 9 in Q2 2025.
- Rosalind Advisors's portfolio value rose 2.6% quarter-over-quarter to $211M.
Based on Rosalind Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.